| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.28% | 85.09% | 89.05% | 86.48% | 30.29% | 20.81% | 4.07% | 32.12% | 28.28% | — | — | — |
| Operating Margin | -975.91% | -758.18% | -311.55% | -302.01% | -1327.07% | -785.44% | -2627.35% | -1341.93% | -4303.21% | — | — | — |
| EBITDA Margin | -970.11% | -753.87% | -308.79% | -299.33% | -1313.42% | -765.01% | -2475.73% | -1323.31% | -4279.32% | — | — | — |
| Net Margin | -829.58% | -705.48% | -283.15% | -292.11% | -1343.96% | -787.03% | -3817.22% | -1315.41% | -4071.48% | — | — | — |
| Current Ratio | 3.36 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 | 3.74 | 6.56 | 15.69 | 22.27 | 55.64 | 11.26 |
| Quick Ratio | 3.36 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 | 3.74 | 6.54 | 15.69 | 22.27 | 55.64 | 11.26 |
| Debt / Equity | — | — | — | — | — | 0.28 | — | 0.14 | — | — | — | — |
| ROE | -62.98% | -84.90% | -56.29% | -43.98% | -46.04% | -135.50% | -230.80% | -61.70% | -30.42% | -28.37% | -22.23% | 41.04% |
| ROA | -40.46% | -59.94% | -44.82% | -34.14% | -36.17% | -72.07% | -164.15% | -48.17% | -28.14% | -27.30% | -21.86% | -49.01% |
| Asset Turnover | 0.05 | 0.08 | 0.16 | 0.12 | 0.03 | 0.09 | 0.04 | 0.04 | 0.01 | — | — | — |
| Book Value / Share | 0.84 | 2.01 | 2.25 | 3.03 | 3.48 | 0.89 | 1.69 | 6.54 | 8.02 | — | — | — |
Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. It operates through two segments: Therapeutics, which identifies and advances innovative therapies to meet unmet needs in conditions such as atopic dermatitis, asthma, and alopecia areata, and Contract Research, which provides laboratory services. Key product candidates include ATI-2138, a potent and selective oral ITK/JAK3 inhibitor demonstrating efficacy in clinical trials for atopic dermatitis and preclinical hair regrowth in alopecia areata models; ATI-052, a bispecific anti-TSLP/IL-4Rα antibody advancing in Phase 1b proof-of-concept trials for atopic dermatitis and asthma with favorable safety, pharmacokinetics, and pharmacodynamics; bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2 trials for moderate-to-severe atopic dermatitis; and others like zunsemetinib and lepzacitinib. Aclaris Therapeutics Inc. targets immune-inflammatory disorders lacking satisfactory treatments, contributing to advancements in immunology through its oral kinase inhibitors and biologics franchises. Founded in 2012 and headquartered in Wayne, Pennsylvania, it plays a role in the biotechnology sector by progressing multiple candidates through clinical development.